xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05980936</url>
    </required_header>
    <id_info>
      <org_study_id>IH.OSAScrnng.2023/2</org_study_id>
      <nct_id>NCT05980936</nct_id>
    </id_info>
    <brief_title>Screening for Obstructive Sleep Apnea in Medical Patients</brief_title>
    <official_title>Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Jordan Collaborating Cardiology Group</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Jordan Collaborating Cardiology Group</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated&#xD;
        with multiple adverse cardiovascular consequences.&#xD;
  &#xD;
        Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness,&#xD;
        loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general&#xD;
        medical wards with these symptoms will be evaluated for the possibility of having OSA.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is&#xD;
        associated with adverse cardiovascular events.&#xD;
  &#xD;
        Screening for OSA is recommended in men and women who have the typical symptoms, including&#xD;
        snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.&#xD;
  &#xD;
        OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias,&#xD;
        and atrial fibrillation.&#xD;
  &#xD;
        Heart failure patients should also be screened for OSA. It is very important to increase the&#xD;
        use of OSA screening especially in patients admitted to the medical floor in tertiary care&#xD;
        hospitals. No study has evaluated this topic in the Middle East in the past.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 15, 2023</start_date>
    <completion_date type="Anticipated">October 1, 2024</completion_date>
    <primary_completion_date type="Anticipated">August 15, 2024</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Case-Only</observational_model>
      <time_perspective>Cross-Sectional</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Number of Participants who are found to have obstructive sleep apnea</measure>
      <time_frame>From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.</time_frame>
      <description>Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA</description>
    </primary_outcome>
    <enrollment type="Anticipated">500</enrollment>
    <condition>Obstructive Sleep Apnea</condition>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Screening for obstructive sleep apnea</intervention_name>
      <description>Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep</description>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Patients without known OSA who are admitted to the general medical ward will be Screened&#xD;
          for signs and symptoms of OSA by answering the questions that have the statement :Do you&#xD;
          have...?&quot;. The symptoms include snoring, day time somnolesce, sudden chocking or gasping&#xD;
          during sleep..&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Willing to sign an informed consent&#xD;
  &#xD;
            -  Patient is admitted to the medical ward in a tertiary hospital&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients known to have obstructive sleep apnea.&#xD;
  &#xD;
            -  Patients younger than 18 years of age&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
    </eligibility>
    <overall_contact>
      <last_name>Ayman Hammoudeh, MD, FACC</last_name>
      <phone>0096265001000</phone>
      <phone_ext>266</phone_ext>
      <email>a.hammoudeh@istisharihospital.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Khalid Assad, MD</last_name>
      <phone>0096265001000</phone>
      <phone_ext>268</phone_ext>
      <email>researchculture2020@gmail.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Istishari Hospital</name>
        <address>
          <city>Amman</city>
          <zip>11888</zip>
          <country>Jordan</country>
        </address>
      </facility>
      <contact>
        <last_name>Ayman Hammoudeh, MD</last_name>
        <phone>0096265001000</phone>
        <phone_ext>266</phone_ext>
        <email>researchculture2020@gmail.com</email>
      </contact>
    </location>
    <location_countries>
      <country>Jordan</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 20, 2023</study_first_submitted>
    <study_first_submitted_qc>August 7, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 8, 2023</study_first_posted>
    <last_update_submitted>August 7, 2023</last_update_submitted>
    <last_update_submitted_qc>August 7, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Obstructive sleep apnea</keyword>
    <keyword>Symptomatology</keyword>
    <keyword>Middle East</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Apnea</mesh_term>
      <mesh_term>Sleep Apnea Syndromes</mesh_term>
      <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05980936
  org study id: IH.OSAScrnng.2023/2
  nct id: NCT05980936
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated
        with multiple adverse cardiovascular consequences.
  
        Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness,
        loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general
        medical wards with these symptoms will be evaluated for the possibility of having OSA.
  Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is
        associated with adverse cardiovascular events.
  
        Screening for OSA is recommended in men and women who have the typical symptoms, including
        snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.
  
        OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias,
        and atrial fibrillation.
  
        Heart failure patients should also be screened for OSA. It is very important to increase the
        use of OSA screening especially in patients admitted to the medical floor in tertiary care
        hospitals. No study has evaluated this topic in the Middle East in the past.
  observational model: Case-Only
  time perspective: Cross-Sectional
  measure: Number of Participants who are found to have obstructive sleep apnea
  time frame: From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.
  description: Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA
  intervention type: Other
  intervention name: Screening for obstructive sleep apnea
  description: Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  last name: Ayman Hammoudeh, MD, FACC
  phone: 0096265001000
  phone ext: 266
  email: a.hammoudeh@istisharihospital.com
  last name: Khalid Assad, MD
  phone: 0096265001000
  phone ext: 268
  email: researchculture2020@gmail.com
  facility: 
  contact: 
  country: Jordan
  responsible party type: Sponsor
  mesh term: Apnea
  mesh term: Sleep Apnea Syndromes
  mesh term: Sleep Apnea, Obstructive